Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells

• Published in: iScience Vol. 26; no. 10; p. 107733
• Main Authors: Singh, Alok K., Wang, Rulin, Lombardo, Kara A., Praharaj, Monali, Bullen, C. Korin, Um, Peter, Gupta, Manish, Srikrishna, Geetha, Davis, Stephanie, Komm, Oliver, Illei, Peter B., Ordonez, Alvaro A., Bahr, Melissa, Huang, Joy, Gupta, Anuj, Psoter, Kevin J., Creisher, Patrick S., Li, Maggie, Pekosz, Andrew, Klein, Sabra L., Jain, Sanjay K., Bivalacqua, Trinity J., Yegnasubramanian, Srinivasan, Bishai, William R.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 20.10.2023; Elsevier
• Subjects: Immune response; Model organism; Virology; Model organism; Immune response; Virology

Bacillus Calmette-Guérin (BCG) confers heterologous immune protection against viral infections and has been proposed as vaccine against SARS-CoV-2 (SCV2). Here, we tested intravenous BCG vaccination against COVID-19 using the golden Syrian hamster model. BCG vaccination conferred a modest reduction...